Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston
5
×
boston blog main
boston top stories
life sciences
national blog main
5
×
national top stories
san francisco blog main
san francisco top stories
5
×
clinical trials
deals
eli lilly
avapritinib
blueprint medicines
fda
genentech
hepatitis b
indiana blog main
indiana top stories
medullary thyroid cancer
new york blog main
new york top stories
non-small cell lung cancer
pralsetinib
roche
selpercatinib
thyroid cancer
alexion pharmaceuticals
aligos therapeutics
alnylam pharmaceutials
arrowhead pharmaceuticals
azacitidine
baker brothers life sciences
benzodiazepine
beta-thalassemia
biotech ipos
blackstone group
blepharitis
boehringer ingelheim
cancer
What
medicines
5
×
approval
blueprint
cancer
drug
drugs
fda
research
ret
abandoning
address
ago
aims
approach
approves
baggage
based
biotech
biotechs
called
candidate
carries
central
certain
cns
companies
currently
cuts
deal
debuts
designed
developing
development
dicerna
disorder
emerged
epigenetic
epigenetics
field
flagship’s
Language
unset
Current search:
medicines
×
biotech
×
" national blog main "
×
boston
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
